Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 275-281

  Kashirskaya, Nataliya Y ^a   Kapranov, Nikolay I ^a   Sander Struckmeier, Suntje ^b   Kovalev, Vladimir ^c  

^a RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^b ABBOTT GMBH AND CO KG   (Germany)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Clinical trial; Creon; Cystic fibrosis; Exocrine pancreatic insufficiency; Pancreatic enzyme replacement therapy; Pancreatin

Indexed keywords

ANTIDIARRHEAL AGENT; BILE ACID; EXPECTORANT AGENT; LAXATIVE; NARCOTIC ANALGESIC AGENT; PANCRELIPASE; RETINOL; SPASMOLYTIC AGENT; VITAMIN D; DRUG DOSAGE FORM; GASTROINTESTINAL AGENT; PANCREATIN;

ACUTE ABDOMEN; ANEMIA; ANTHROPOMETRY; ANUS FISSURE; ARTICLE; BALANITIS; BODY HEIGHT; BODY MASS; BODY WEIGHT; CAREGIVER; CHALAZION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DEFECATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; ENZYME REPLACEMENT; FEMALE; FOOD ALLERGY; GROWTH CURVE; HUMAN; INFANT; MALE; MULTICENTER STUDY; OPEN STUDY; OTITIS MEDIA; PANCREAS EXOCRINE INSUFFICIENCY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; RUSSIAN FEDERATION; STEATORRHEA; STOMATITIS; TREATMENT DURATION; ADVERSE EFFECTS; CLINICAL TRIAL; COMPLICATION; DEVICES; DRUG DOSAGE FORM; EXOCRINE PANCREATIC INSUFFICIENCY; PROCEDURES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

CHILD, PRESCHOOL; CYSTIC FIBROSIS; DIARRHEA; DOSAGE FORMS; ENZYME REPLACEMENT THERAPY; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT; MALE; PANCREATIN; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84924290753     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.07.006     Document Type: Article

References (26)

1. O'Sullivan B.P., Baker D., Leung K.G., Reed G., Baker S.S., Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr 2013, 162:808-812. [e1].
2. Walkowiak J., Lisowska A., Blaszczynski M. The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype. Eur J Gastroenterol Hepatol 2008, 20:157-160.
3. Bronstein M.N., Sokol R.J., Abman S.H., Chatfield B.A., Hammond K.B., Hambidge K.M., et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992, 120:533-540.
4. Domínguez-Muñoz J.E. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 2007, 9:116-122.
5. Yen E.H., Quinton H., Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 2013, 162:530-535. [e1].
6. Lai H.J., Shoff S.M., Farrell P.M. Recovery of birth weight z score within 2years of diagnosis is positively associated with pulmonary status at 6years of age in children with cystic fibrosis. Pediatrics 2009, 123:714-722.
7. Konstan M.W., Butler S.M., Wohl M.E., Stoddard M., Matousek R., Wagener J.S., et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003, 142:624-630.
8. Steinkamp G., Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002, 57:596-601.
9. Beker L.T., Russek-Cohen E., Fink R.J. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc 2001, 101:438-442.
10. Stallings V.A., Stark L.J., Robinson K.A., Feranchak A.P., Quinton H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008, 108:832-839.
11. Sinaasappel M., Stern M., Littlewood J., Wolfe S., Steinkamp G., Heijerman H.G., et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002, 1:51-75.
12. Borowitz D., Robinson K.A., Rosenfeld M., Davis S.D., Sabadosa K.A., Spear S.L., et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009, 155:S73-S93.
13. Abbott Healthcare Products Limited Creon® Micro Summary of Product Characteristics [Accessed on December 11, 2013]; Available from:. http://www.medicines.org.uk/emc/medicine/14989/SPC.
14. Colombo C., Fredella C., Russo M.C., Faelli N., Motta V., Valmarana L., et al. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas 2009, 38:693-699.
15. Munck A., Duhamel J.F., Lamireau T., Le Luyer B., Le Tallec C., Bellon G., et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibros 2009, 8:14-18.
16. Graff G.R., McNamara J., Royall J., Caras S., Forssmann K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. Clin Drug Investig 2010, 30:351-364.
17. Graff G.R., Maguiness K., McNamara J., Morton R., Boyd D., Beckmann K., et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther 2010, 32:89-103.
18. Heeley M.E., Woolf D.A., Heeley A.F. Indirect measurements of sweat electrolyte concentration in the laboratory diagnosis of cystic fibrosis. Arch Dis Child 2000, 82:420-424.
19. European Medicines Agency ICH topic E 11: clinical investigation of medicinal products in the paediatric population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99) [Accessed on November 14, 2013]; Available from:. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf.
20. Borowitz D.S., Grand R.J., Durie P.R. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 1995, 127:681-684.
21. Kuczmarski R.J., Ogden C.L., Guo S.S., Grummer-Strawn L.M., Flegal K.M., Mei Z., et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 2002, 11:1-190.
22. Park K.K., Brodell R.T., Helms S.E. Angular cheilitis, part 2: nutritional, systemic, and drug-related causes and treatment. Cutis 2011, 88:27-32.
23. Baccaglini L., Lalla R.V., Bruce A.J., Sartori-Valinotti J.C., Latortue M.C., Carrozzo M., et al. Urban legends: recurrent aphthous stomatitis. Oral Dis 2011, 17:755-770.
24. Wooldridge J.L., Heubi J.E., Amaro-Galvez R., Boas S.R., Blake K.V., Nasr S.Z., et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros 2009, 8:405-417.
25. Weaver L.T., Steiner H. The bowel habit of young children. Arch Dis Child 1984, 59:649-652.
26. Fontana M., Bianchi C., Cataldo F., Conti Nibali S., Cucchiara S., Gobio Casali L., et al. Bowel frequency in healthy children. Acta Paediatr Scand 1989, 78:682-684.